Divi's Laboratories shares in focus on EU panel backing
In short
Divi's Laboratories shares were in focus after a report said a weight loss drug got backing from an EU panel. Analysts think Divi's may be an intermediate supplier of orforglipron.
This could affect the stock in trading, but the report does not confirm a deal, a timeline, or any sales impact.
What the reporting says
Divi's Laboratories shares were in focus after a report said a weight loss drug received backing from an EU panel. CNBC TV18 Market said analysts believe Divi's Laboratories is likely to be an intermediate supplier of orforglipron for weight loss. The report does not confirm a contract, timeline, or earnings impact, so any trading reaction remains uncertain.
Why it matters
Divi's Laboratories shares moved into focus after a publisher summary said a weight loss drug received EU panel backing. Analysts were cited as believing Divi's may act as an intermediate supplier of orforglipron. The reporting does not confirm a supply agreement, any financial benefit, or the timing of any market reaction.